2018 was a rough year for OPK. As we start into 2019 we should see Rayslder sales growth through next year, an SEC settlement announced, FDA Claros decision, Phase 3 HGH for children, Vifor Pharma commercializing Rayaldee, and more...
Lots of money to be made in the swine market. Of course negatives dumbass trolls are a dying breed. Maybe you can find a good pod to latch onto.
Looks like one of the predictions for told came just came true. OPK just settled with SEC for $100k....
That was opko’s penalty. Frost has to pay a $5.5M penalty (thats like us regular folks paying $500). He will pay without having to admit or deny the charges. Something not right here. Sounds like the SEC just wanted his money. Can you say extortion?
I wouldn’t call it extortion. The man is worth something like 4 billion. In the grand scheme of things the Fed’s probably didn’t net that much after costs. The company, on the other hand, probably spent a considerable sum in attorney fees. That cost will be put on the backs of shareholders and employees. Most telling to me is the ban on trading in penny stocks.
Phase 2b in diabetes and obesity means 3-4 years away for obesity and 2-3 years for diabetes to obtain meaningful outcomes in your Phase 3a and 3b trials. Good news yes, now we have to last that long and so does Frost, if not we are going to be sold. But you knew that right, or are you like many around here who blames the previous rep for your misfortunes do to your lack of industry knowledge and all around ingnorance.
Blah, blah, blah, sounds a lot like the many blow jobs you had to perform in order to obtain your first job in pharma. at Opko.
They could partner with a company like Vifor to take the EU rights for a upfront fee and share with phase three costs. Just a thought..,
